{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:41:12Z","timestamp":1777963272660,"version":"3.51.4"},"reference-count":20,"publisher":"Galenos Yayinevi","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjps"],"DOI":"10.4274\/tjps.galenos.2025.70718","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T07:41:56Z","timestamp":1754034116000},"page":"191-206","source":"Crossref","is-referenced-by-count":1,"title":["Simultaneous Quantification of Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate in Human Plasma by UPLC-MS\/MS: Method Development and Validation"],"prefix":"10.4274","volume":"22","author":[{"given":"Narasimha","family":"KANJARLA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balaraju","family":"KATTA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41572-023-00452-3","article-title":"HIV infection","volume":"9","author":"Bekker","year":"2023","unstructured":"1. Bekker LG, Beyrer C, Mgodi N, Lewin SR, Delany-Moretlwe S, Taiwo B, Masters MC, Lazarus JV. HIV infection. Nat Rev Dis Primers. 2023;9:42.","journal-title":"Nat Rev Dis Primers"},{"key":"ref1","unstructured":"2. Full Prescribing Information (PIL) of Delstrigo Tablets, US FDA."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/COH.0000000000000471","article-title":"Doravirine: a review","volume":"13","author":"MA","year":"2018","unstructured":"3. Colombier MA, Molina JM. Doravirine: a review. Curr Opin HIV AIDS. 2018;13:308-314.","journal-title":"Curr Opin HIV AIDS"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s40262-019-00806-9","article-title":"Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of Doravirine","volume":"58","author":"Boyle","year":"2019","unstructured":"4. Boyle A, Moss CE, Marzolini C, Khoo S. Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of Doravirine. Clin Pharmacokinet. 2019;58:1553-1565.","journal-title":"Clin Pharmacokinet"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Blevins SR, Hester EK, Chastain DB, Cluck DB. Doravirine: a return of the NNRTI class? Ann Pharmacother. 2020;54:64-74.","DOI":"10.1177\/1060028019869641"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-199936010-00004","article-title":"Clinical pharmacokinetics of Lamivudine","volume":"36","author":"Johnson","year":"1999","unstructured":"6. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of Lamivudine. Clin Pharmacokinet. 1999;36:41-66.","journal-title":"Clin Pharmacokinet"},{"key":"ref6","unstructured":"7. Taylor K, Fritz K, Pellegrini MV, Parmar M. Lamivudine. 2024 Feb 28. In: StatPearls [Internet]."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1517\/17425250903490418","article-title":"Lamivudine for the treatment of HIV","volume":"6","author":"PN","year":"2010","unstructured":"8. Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol. 2010;6:105-114.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1086\/378068","article-title":"Tenofovir Disoproxil Fumarate","volume":"37","author":"JE","year":"2003","unstructured":"9. Gallant JE, Deresinski S. Tenofovir Disoproxil Fumarate. Clin Infect Dis. 2003;37:944-950.","journal-title":"Clin Infect Dis"},{"key":"ref9","unstructured":"10. Miller MD. K65R, TAMs and tenofovir. AIDS Rev. 2004;6:22-33."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/microorganisms11010221","article-title":"HIV and drug-resistant subtypes","volume":"11","author":"Nastri","year":"2023","unstructured":"11. Nastri BM, Pagliano P, Zannella C, Folliero V, Masullo A, Rinaldi L, Galdiero M, Franci G. HIV and drug-resistant subtypes. Microorganisms. 2023;11:221.","journal-title":"Microorganisms"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","article-title":"Switching to Doravirine\/Lamivudine\/ Tenofovir Disoproxil Fumarate (DOR\/3TC\/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial","volume":"81","author":"Johnson","year":"2019","unstructured":"12. Johnson M, Kumar P, Molina JM, Rizzardini G, Cahn P, Bickel M, Mallolas J, Zhou Y, Morais C, Kumar S, Sklar P, Hanna GJ, Hwang C, Greaves W; DRIVE-SHIFT Study Group. Switching to Doravirine\/Lamivudine\/ Tenofovir Disoproxil Fumarate (DOR\/3TC\/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr. 2019;81:463-472.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Kokkirala TK, Kancherla P, Alegete P, Suryakala D. A simple alternative and improved HPLC method for the estimation of Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate in solid oral dosage form. Biomed Chromatogr. 2021;35:e5121.","DOI":"10.1002\/bmc.5121"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4274\/tjps.galenos.2020.70962","article-title":"Development and validation of a stability-indicating RP-HPLC method for the simultaneous estimation of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate","volume":"18","author":"Attaluri","year":"2021","unstructured":"14. Attaluri T, Seru G, Varanasi SNM. Development and validation of a stability-indicating RP-HPLC method for the simultaneous estimation of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate. Turk J Pharm Sci. 2021;18:410-419.","journal-title":"Turk J Pharm Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.5530\/ijper.56.4.201","article-title":"Bio-analytical method development and validation for simultaneous determination of bictegravir, emtricitabine, and tenofovir alafenamide fumarate in human plasma by LC-MS\/MS","volume":"56","author":"Tanuja","year":"2022","unstructured":"15. Tanuja A, Ganapaty S. Bio-analytical method development and validation for simultaneous determination of bictegravir, emtricitabine, and tenofovir alafenamide fumarate in human plasma by LC-MS\/MS. Indian Journal of Pharmaceutical Education and Research. 2022;56:1190-1205.","journal-title":"Indian Journal of Pharmaceutical Education and Research"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"115010","DOI":"10.1016\/j.jpba.2022.115010","article-title":"Validation of an LC-MS\/MS assay for the simultaneous determination of bictegravir, Doravirine, and raltegravir in human plasma","volume":"220","author":"Schauer","year":"2022","unstructured":"16. Schauer AP, Sykes C, Cottrell ML, Imaz A, Podzamczer D, Kashuba AD. Validation of an LC-MS\/MS assay for the simultaneous determination of bictegravir, Doravirine, and raltegravir in human plasma. J Pharm Biomed Anal. 2022;220:115010.","journal-title":"J Pharm Biomed Anal"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Marakatham S, Shanmugapandiyan P. Bioanalytical method development and validation of Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate using HPLC in human plasma. Research Journal of Pharmacy and Technology. 2021;14:4087-4091.","DOI":"10.52711\/0974-360X.2021.00708"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.pharma.2021.04.006","article-title":"A simple stability indicating RP-HPLC-DAD method for concurrent analysis of Tenofovir Disoproxil Fumarate, Doravirine and Lamivudine in pure blend and their combined film coated tablets","volume":"79","author":"Godela","year":"2021","unstructured":"18. Godela R, Gummadi S. A simple stability indicating RP-HPLC-DAD method for concurrent analysis of Tenofovir Disoproxil Fumarate, Doravirine and Lamivudine in pure blend and their combined film coated tablets. Ann Pharm Fr. 2021;79:640-651.","journal-title":"Ann Pharm Fr"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pharma.2022.08.006","article-title":"Simultaneous determination of emtricitabine, tenofovir alafenamide fumarate and dolutegravir sodium by validated stability-indicating RP-HPLC-DAD method","volume":"81","author":"Rathod","year":"2023","unstructured":"19. Rathod SM, Patel NC, Patel PU. Simultaneous determination of emtricitabine, tenofovir alafenamide fumarate and dolutegravir sodium by validated stability-indicating RP-HPLC-DAD method. Ann Pharm Fr. 2023;81:94-106.","journal-title":"Ann Pharm Fr"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3851\/IMP3324","article-title":"No meaningful drug interactions with Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate coadministration","volume":"24","author":"Anderson","year":"2019","unstructured":"20. Anderson MS, Gilmartin J, Fan L, Yee KL, Kraft WK, Triantafyllou I, Reitmann C, Guo Y, Liu R, Iwamoto M. No meaningful drug interactions with Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate coadministration. Antivir Ther. 2019;24:443-450.","journal-title":"Antivir Ther"}],"container-title":["Turkish Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T06:10:50Z","timestamp":1754374250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.turkjps.org\/articles\/simultaneous-quantification-of-doravirine-lamivudine-and-tenofovir-disoproxil-fumarate-in-human-plasma-by-uplc-msms-method-development-and-validation\/doi\/tjps.galenos.2025.70718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.4274\/tjps.galenos.2025.70718","relation":{},"ISSN":["1304-530X","2148-6247"],"issn-type":[{"value":"1304-530X","type":"print"},{"value":"2148-6247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}